@article {Fuhrp3979, author = {Rainard Fuhr and Helgo Magnussen and David Singh and Gonzalo de Miquel and Cynthia Caracta and Esther Garcia Gil}, title = {Patient assessments of ease of use of Genuair{\textregistered} versus Aerolizer{\textregistered} and HandiHaler{\textregistered}}, volume = {38}, number = {Suppl 55}, elocation-id = {p3979}, year = {2011}, publisher = {European Respiratory Society}, abstract = {Introduction: The Genuair{\textregistered}* inhaler, a multidose, dry powder inhaler, has been developed to provide reliable and effective delivery of inhaled medications including aclidinium bromide, which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD).Aim: To report data from two Phase II studies that included patient assessments of the convenience of Genuair{\textregistered} versus Aerolizer{\textregistered} and HandiHaler{\textregistered}, respectively.Methods: Both studies were randomised, double-blind, double-dummy, cross-over trials in patients with moderate to severe COPD. In the first study, 79 patients received treatment over seven-day periods via Genuair{\textregistered} and Aerolizer{\textregistered}. In the second study, 30 patients received treatment over 15-day periods via Genuair{\textregistered} and HandiHaler{\textregistered}. At the end of the studies, patients were asked to evaluate their impressions of inhaler conveniences.Results: Patient assessments of the different inhalers are presented in Table 1.Conclusions: Patient assessments of convenience were higher for the Genuair{\textregistered} inhaler versus the Aerolizer{\textregistered} or HandiHaler{\textregistered}.These studies were supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc, New York, USA.*Genuair{\textregistered} is a registered trademark of Almirall S.A.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/38/Suppl_55/p3979}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }